Sarasota, Fla. – September 11, 2026 -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026.
Shanghai – September 11, 2026 -- Alebund Pharmaceuticals (Jiangsu) Limited (HKEX: 09637) has received U.S. FDA clearance of its Investigational New Drug application for AP308, a first-in-class engineered recombinant IgA protease targeting IgA Nephropathy (IgAN), moving the candidate from preclinical research into clinical development.
San Diego – September 11, 2026 -- Inhibrx Biosciences reported that its OX40 agonist INBRX-106, combined with pembrolizumab, produced a 48.3% confirmed objective response rate in first-line head and neck squamous cell carcinoma patients, nearly double the 26.5% seen with pembrolizumab alone.
Yongin, South Korea – September 11, 2026 -- GCCL (Global Clinical Central Lab), a South Korea-based clinical trial sample analysis provider, sponsored the Asia Bio Partnering Forum 2026 (ABP 2026) as a Platinum Sponsor, using the Singapore event to pursue expansion of its assay development and clinical sample analysis services across the Asia-Pacific region.
Irvine, California – September 10, 2026 -- PeproMene Bio, Inc. reported that seven of nine patients (80%) treated with its BAFF-R-targeted CAR-T therapy PMB-CT01 achieved complete remission in a Phase 1 trial, with results now published in The Lancet.
New York – September 10, 2026 -- Capricor Therapeutics, Inc. (NASDAQ:CAPR) faces a securities fraud class action after its shares plunged 64.5% following disclosures about alleged undisclosed changes to clinical trial statistics underlying its Duchenne muscular dystrophy therapy application.
Gothenburg – – September 10, 2026 -- Epicyt Pharma AB reported positive topline results from a Phase 1/2a first-in-human study of its oral drug candidate BAFA, showing a statistically significant reduction in urinary calcium excretion in patients who underwent Roux-en-Y gastric bypass (RYGB) surgery. The Gothenburg-based clinical-stage biopharmaceutical company said the trial, completed in March 2026, also recorded improvements in key biomarkers of calcium homeostasis, consistent with enhanced intestinal calcium uptake.
Los Angeles – September 10, 2026 -- Schall, Brown & Schwartz LLP (SBS) has issued a reminder to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a securities class action lawsuit alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The lead plaintiff deadline is set for September 28, 2026.
Yongin, South Korea – September 10, 2026 -- GCCL (Global Clinical Central Lab), a South Korea-based clinical trial sample analysis provider, served as a Platinum Sponsor at the Asia Bio Partnering Forum 2026 (ABP 2026) in Singapore, held from August 31 to September 2, as it pursued expansion of its assay development and sample analysis services across the Asia-Pacific region.
Los Angeles – September 10, 2026 -- DJS Law Group has reminded shareholders of a class action lawsuit filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The suit covers investors who purchased BBNX shares between July 30, 2025 and February 24, 2026, with a lead plaintiff filing deadline set for November 3, 2026.
